Lupin gets USFDA EIR for Ankleshwar unit
The inspection of the facility was conducted from August 16-19, 2022.
Mumbai: Global pharma major Lupin Limited has announced that the Company has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Ankleshwar manufacturing facility, located in Gujarat, India.
The inspection of the facility was conducted from August 16-19, 2022.
Commenting on the development, Nilesh Gupta, Managing Director, Lupin, said, "We are very happy to have received the EIR for our Ankleshwar facility from US FDA. We remain committed to enhancing compliance and quality standards across all our manufacturing sites."
Read also: Lupin unveils generic equivalent of Revatio for Oral Suspension in US
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions. The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women's health areas.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd